Yes, Roundhill S&P Dividend Monarchs ETF (KNGS) holds JNJ with 3.25% (as of 2026-09-23).

Yes, Vanguard Dividend Appreciation ETF (VIG) holds JNJ with 2.73% (as of 2026-09-23).

Yes, Vanguard Value ETF (VTV) holds JNJ with 2.33% (as of 2026-09-23).

Yes, iShares Russell 1000 Value ETF (IWD) holds JNJ with 1.70% (as of 2026-09-23).

Johnson & Johnson (JNJ) is held by KNGS (3.25%), VIG (2.73%), VTV (2.33%), IWD (1.70%).

What sector is JNJ in?

Johnson & Johnson is classified under GICS Health Care (Pharmaceuticals).

What is JNJ's last close price?

JNJ last closed at $270.68 on 2026-09-24.

JNJ

Johnson & Johnson

Health Care · Pharmaceuticals

$270.68last close

+53.2%~252d

Price

+53.19% over 1Y

Thesis

as of 2026-09-23

Bull case

Structural: post-Kenvue pure-play healthcare with two engines - Innovative Medicine (~63% of rev) and MedTech (~37%). 9B 2023 rev, ~16% of group) losing US exclusivity 2026 with biosimilar erosion already underway, against ramping replacement franchises (Tremfya, Darzalex, Carvykti, Erleada) and Abiomed-led MedTech reacceleration.

Talc litigation overhang remains binary tail risk.

- Tremfya + Darzalex + Carvykti + Erleada portfolio sized to bridge Stelara LOE per management guide; oncology pipeline (CAR-T, bispecifics) underappreciated

- Abiomed Impella high-single-digit growth + cardiovascular tuck-ins reposition MedTech as the secular growth leg

- Dividend King status + ~3% yield + AAA balance sheet = defensive bid in risk-off; buyback optionality

- Kenvue separation removed lower-margin drag; group operating margin re-rates structurally higher

Bear case

- Stelara biosimilar ramp 2024-2026 is the largest LOE step-down in JNJ history; replacement franchise execution is not free

- Talc multi-district litigation: bankruptcy strategy challenged twice, settlement range still wide; tail risk caps multiple

- Pharma pricing/IRA Medicare negotiation lists Xarelto + Imbruvica; future-rounds risk for Stelara, Darzalex

- Mega-cap healthcare has underperformed broad indices through the GLP-1 / AI rotation; multiple compression risk if growth disappoints

Follow $JNJ and the AI trade, free.

Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.

No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.

Analyze JNJ· interactive tools

Top correlated· 252d co-movement

0.49
0.46
0.45
0.42
0.42
0.41

Frequently asked questions

Is JNJ in KNGS?: Yes, Roundhill S&P Dividend Monarchs ETF (KNGS) holds JNJ with 3.25% (as of 2026-09-23).
Is JNJ in VIG?: Yes, Vanguard Dividend Appreciation ETF (VIG) holds JNJ with 2.73% (as of 2026-09-23).
Is JNJ in VTV?: Yes, Vanguard Value ETF (VTV) holds JNJ with 2.33% (as of 2026-09-23).
Is JNJ in IWD?: Yes, iShares Russell 1000 Value ETF (IWD) holds JNJ with 1.70% (as of 2026-09-23).
What ETFs hold JNJ?: Johnson & Johnson (JNJ) is held by KNGS (3.25%), VIG (2.73%), VTV (2.33%), IWD (1.70%).
What sector is JNJ in?: Johnson & Johnson is classified under GICS Health Care (Pharmaceuticals).
What is JNJ's last close price?: JNJ last closed at $270.68 on 2026-09-24.

•2026 Q1: Stelara US biosimilar competition begins (Amgen Wezlana, Alvotech); first quarter of step-down disclosed in segment pharma
•2023 Dec: Kenvue ($KVUE) consumer-health separation completed via exchange offer; ~$13B cash returned
•2023 Q1: Abiomed acquisition closed (~$16.6B); Impella heart pump franchise folded into MedTech cardiovascular
•2023: Darzalex Faspro + Tremfya + Erleada each cross $4B run rate; oncology + immunology growth pillars established
•2024-2026: Carvykti (CAR-T, multiple myeloma, partnered with $LEGN) ramping toward blockbuster status
•Medicare IRA negotiation: Xarelto + Imbruvica in first list (effective 2026); Stelara likely future round

Key levels

$240.83
0.382 retr of 175.74->281.07 (52w) · 2026-09-24
Out of reach · reference only
+12.4%
$228.41
0.5 retr of 175.74->281.07 (52w) · 2026-09-24
Out of reach · reference only
+18.5%
$215.98
0.618 retr of 175.74->281.07 (52w) · 2026-09-24
Out of reach · reference only
+25.3%
$198.28
0.786 retr of 175.74->281.07 (52w) · 2026-09-24
Out of reach · reference only
+36.5%

Price has moved beyond every level on record here. They are kept as structural reference, not as an entry map.

Open full Fib grid →Correlation lookup →🔔 Get Telegram alerts for $JNJ →

Facts

Exchange: US
Currency: USD
Market cap: $648.67B
Last update: 2026-09-24

Revenue (TTM)$97.9B

P/E31.3×

P/S6.6×

Net margin21.5%

JNJ